Internal Pipeline
Undisclosed GPCR targets
Key Facts
About InterAx Biotech
InterAx Biotech is a private, preclinical-stage company leveraging a sophisticated systems biology platform to de-risk and accelerate GPCR drug discovery. Its core Deep Signal™ technology aims to translate a deep understanding of cellular signaling pathways into differentiated drug candidates with superior therapeutic profiles. With a seasoned leadership team and strong academic ties, particularly to the Paul Scherrer Institute and ETH Zürich, the company is positioned to address high-value targets in the GPCR space, a historically challenging but highly druggable family of proteins.
View full company profileAbout ExpressionEdits
ExpressionEdits is a private, preclinical-stage biotech leveraging computational biology to solve a fundamental bottleneck in biotechnology: inefficient protein expression. Its core innovation, the Genetic Syntax Engine, uses AI to design synthetic introns and optimize genetic 'grammar,' enabling high-yield production of complex proteins for therapeutics. The company is pursuing a dual strategy of building its own pipeline of high-value protein drugs and forming strategic collaborations, as evidenced by its recent partnership with Boehringer Ingelheim. Backed by a $13M seed round and a team with deep expertise in genomics and machine learning, ExpressionEdits aims to modernize the genetic toolbox for next-generation medicines.
View full company profile